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Abstract
Aggrecan is one of the two major constituents of articular cartilage, and during diseases such as
osteoarthritis (OA) it is subject to degradation by proteolytic enzymes. The primary proteases
responsible for aggrecan cleavage are the aggrecanases, identified as members of the ADAMTS
family of proteases, which are upregulated in response to inflammatory stimuli. It is uncertain
which of the 6 aggrecanases (ADAMTS-1, -4, -5, -8, -9 and -15) are primarily responsible for the
degradation of aggrecan in human cartilage. Here we show that 4 of the 6 aggrecanases are
expressed in immortalized chondrocyte cell-lines and can be up-regulated in response to
inflammatory cytokines. Using RNA interference, we demonstrate robust knockdown of
ADAMTS-5 and -9 expression in these cells, and by culturing them on 3 dimensional scaffolds,
show that reduction in expression of ADAMTS-5 enzyme results in an increase in matrix
deposition. These data suggest that the quality of tissue-engineered cartilage matrix might be
improved by targeted depletion of aggrecanase expression. Moreover, this work also provides
further evidence that ADAMTS-5 may be a therapeutic target in the treatment of arthritic disease.
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1. Introduction
Articular cartilage is largely comprised of type II collagen and aggrecan, both of which are
secreted by chondrocytes. Collagen, with its fibrillar structure, provides the tissue with its
tensile strength, while aggrecan, a large aggregating proteoglycan, is associated with
resistance to compression. An appropriate balance of secretion, organization and turnover of
matrix molecules by cartilage chondrocytes is crucial to proper maintenance of the tissue.
While the rate of turnover is low in normal adult articular cartilage, in arthritic diseases such
as osteoarthritis (OA), this is enhanced, under the influence of inflammatory mediators such
as interleukin-1 (IL-1) and tumour-necrosis factor (TNF) (Mort et al., 1993; Saklatvala,
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1986; Mohammed-Ali, 1995). In this situation the rate of breakdown exceeds that of
synthesis, leading to gradual and irreversible loss of cartilage and thereby joint function (for
reviews, see Mort and Billington, 2001; Arner, 2002; Caterson et al., 2000; Nagase and
Kashiwagi, 2003).
The most important effectors of cartilage matrix degradation in both homeostasis and
pathology are resident proteolytic enzymes whose expression can be upregulated by IL-1
and TNF. Matrix metalloproteinases (MMPs) degrade collagen in an irreversible event
(Billinghurst et al., 1997; Ohuchi et al., 1997; Knaüper et al., 1996), while aggrecan is
degraded in an earlier and reversible manner, mainly by the aggrecanase enzymes (Arner et
al., 1999; Lohmander et al., 1993; Sandy and Verscharen, 2001), at a characteristic cleavage
site within the interglobular domain (Sandy et al., 1991). MMP and aggrecanase cleavage
products of both collagen and aggrecan have been identified in the synovial fluid of arthritic
patients (Lohmander et al., 1993; Sandy et al., 1992; Hollander et al., 1994), as well as in
the conditioned media of cartilage explants stimulated with IL-1 (Arner et al., 1999; Dodge
et al., 1989)
Aggrecanases are members of the ADAMTS (a-disintegrin and metalloproteinase with
thrombospondin type I motifs) family of proteinases (Porter et al., 2005), ADAMTS-4 and
ADAMTS-5 being the most studied (aggrecanase-1 and -2 respectively) (Tortorella et al.,
1999; Abbaszade et al., 1999). In transgenic mice, ADAMTS-5 appears to be predominantly
responsible for aggrecan breakdown in models of arthritis (Stanton et al., 2005; Glasson et
al., 2005; Little et al., 2005), whereas in other species, ADAMTS-4 may be more important
(Powell et al., 2007; Tortorella et al., 2001). In human cartilage explants, a recent report
implicated both ADAMTS-4 and -5 in tissue breakdown (Song et al., 2007), however
ADAMTS-1, -8, -9 and -15 also have aggrecanase activity in vitro (Rodríguez-Manzaneque
et al., 2002; Kuno et al., 2000; Collins-Racie et al., 2004; Somerville et al., 2003; Yamaji et
al., 2001), and there has been no study to definitively identify the principle enzyme(s)
responsible.
This study describes the use of targeted shRNA-expressing lentiviruses to knock-down the
expression of specific aggrecanases in a chondrocyte cell-line. Using C-28/I2 cells, which
we have previously shown to produce some rudimentary extracellular matrix (ECM) when
grown in 3D culture (Finger et al., 2003), we have undertaken a preliminary investigation of
the functional effect of aggrecanase knock-down on matrix deposition.
2. Materials and Methods
2.1. Materials
Tissue culture reagents were from Sigma-Aldrich (Poole, UK), cytokines from Peprotech
(London, UK), plasticware from Nunc (Loughborough, UK) and Iwaki (SLS, Nottingham,
UK). Molecular biological reagents were from Promega (Southampton, UK). Plasmid
extraction kits were the ‘Endofree’ type from Qiagen (Crawley, UK).
2.2. Monolayer cell culture and stimulation
T/C-28a2, C-20/A4 and C-28/I2 chondrocyte cell-lines have been previously described
(Goldring et al., 1994; Finger et al., 2003). 293T and GP2-293 cells were obtained from
American Type Culture Collection (Teddington, UK). All cells were maintained in
DMEM:F12 with ‘Glutamax’ (Invitrogen, Paisley, UK); 10 % FCS; Penicillin (100 U/ml)/
Streptomycin (0.1 mg/ml). For cytokine stimulation, cells were incubated for 6h with a
cytokine mix (10ng/ml IL1-ȕ, 500ng/ml TNF-Į, 1,000U/ml IFN-Ȗ).
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2.3. Lentiviral and retroviral short hairpin RNA constructs
Cloned shRNA-lentiviral construct target sets for the two aggrecanases were from the
MISSION™ TRC-Hs 1.0 (Human) library, designed by the RNAi consortium and available
via Sigma-Aldrich (Poole, UK) (Moffat et al., 2006). Unique construct designations used
were TRCN0000050493 to 50497 (ADAMTS-5) and TRCN0000046633 to 46637
(ADAMTS-9). Controls were the ‘scrambled’ (non-targeting) shRNA expression construct
and the empty cloning vector, also obtained from the RNAi consortium via Sigma.
Packaging vectors were psPAX2 and pMD2.G, obtained from Addgene
(http://www.addgene.org/pgvec1). RNAi-Ready pSIREN-RetroQ vector from BD
Biosciences (Oxford, UK) was used to create retroviral DNA constructs (Coughlan et al.,
2009) and retroviral packaging plasmid (pVSV-G) was obtained from Clontech-Takara Bio
Europe (France).
2.4. Transfection and transduction
To make lentivirus, 293T cells were plated into collagen-coated 10 cm dishes, and
transfected at 50–80 % confluence using the calcium phosphate precipitation method and 14
µg lentiviral shRNA construct, 12 µg psPAX2, and 4 µg pMD2.G. Retroviruses were made
similarly, by transfection of GP2-293 cells with 15 µg of shRNA construct and 15 µg of
pVSV-G. Virus-containing supernatant was collected 48 h later and centrifuged for 5 min at
3 000 × g to remove cell debris, before aliquotting and storing at ᙐ80 °C. Virus was titered
by transduction of serial dilutions onto chondrocytes in the presence of 8 µg/ml polybrene
followed by selection in 800 ng/ml puromycin. For knock-down experiments, C-28/I2
chondrocytes were transduced in 10 cm dishes with between 70 000 and 20 000 000 cfu
virus, which was sufficient to achieve ~ 90 % knock-down of gene expression without being
toxic to cells. After puromycin selection, transduced cells were grown up and cryo-stored to
preserve the cell-lines as well as a T75 flask of cells being collected in 4 ml TRI-reagent
(Sigma-Aldrich) for RNA preparation.
2.5. RNA extraction and real-time RT-PCR
Total RNA was isolated from cells using TRI-reagent (Sigma-Aldrich) according to the
manufacturer's protocol, and subsequently DNAse-treated. Reverse transcription was carried
out using 2 µg RNA as template, and incubating with 0.5 µg random hexamer primers for 5
min at 70 °C, before adding 1× buffer, 40 U RNAsin, 200 U MMLV reverse transcriptase
(Promega, Southampton, UK) and 2 mM each dNTP, and incubating at 37 °C for 1 h
followed by 70 °C for 5 min.
A set of 13 cDNA standards was generated by reverse transcription of known amounts of
cytokine-stimulated cellular RNA. cDNA templates including standards were plated in
triplicate into separate 386-well optical plates (Greiner, Stonehouse, UK) for analysis of
each transcript. Reaction mix added to each well consisted of 1× QPCR buffer (Eurogentec,
Southampton, UK); 200 nM each primer, and 100 nM FAM/TAMRA labeled probe
(Eurogentec). Primers and probes were designed using ‘Primer express’ software (ABI) and
sequences were as follows:
ADAMTS-1FOR 5’-ggacaggtgcaagctcatctg
ADAMTS-1REV 5’-tctacaaccttgggctgcaaa
ADAMTS-1probe 5’-caagccaaaggcattggctacttcttcg
ADAMTS-4FOR 5’-gtcccatgtgcaacgtcaag
ADAMTS-4REV 5’-tcatctgccaccaccagtgt
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ADAMTS-4probe 5’-ttcgcgaaacgaagtgactcatctaaacacc
ADAMTS-5FOR 5’-ggctcacgaaatcggacatt
ADAMTS-5REV 5’-ggaaccaaaggtctcttcacaga
ADAMTS-5probe 5’-tggcctctcccatgacgattccaa
ADAMTS-8FOR 5’-agtgttcgaggccaaggtgat
ADAMTS-8REV 5’-ctggccacggacacagatg
ADAMTS-8probe 5’-caccctgtgtgggccagaaacac
ADAMTS-9FOR 5’-ccctgagaccaagccaacat
ADAMTS-9REV 5’-gctggtatccctgtccacaag
ADAMTS-9probe 5’-tgcatcctggcaggcgggtc
ADAMTS-15FOR 5’-gtgaaataccgatcctgcaatct
ADAMTS-15REV 5’-gtagccgttgaaagcctcaca
ADAMTS-15probe 5’-tcagcctccggaaagagcttccg
Cyclo-EFOR 5’-ggagggagagcccattgc
Cyclo-EREV 5’-ggcttgttcccaatcttgatg
Cyclo-Eprobe 5’-cccgctcaaatcctcaggtgtacatgg
Primer and probe sequences for detection of aggrecan and collagen II transcripts were as
follows (Kurth et al., 2007):
Aggrecan_F 5'-ctaccgctgcgaggtgatg
Aggrecan_R 5'-tcgagggtgtagcgtgtagaga
Aggrecan probe 5'-atggaacacgatgcctttcaccacga
ColIIA1_F 5'-ggcaatagcaggttcacgtaca
ColIIA1_R 5'-cgataacagtcttgccccactt
ColIIA1 probe 5'-ccggtatgtttcgtgcagccatcct
Real-time PCR reactions were carried out and analyzed using a Prism 7900 sequence
detection system (ABI, Foster City, CA, USA). Relative starting amount of transcripts was
interpolated from the standard curves.
2.6. Tissue constructs
For each transduced C-28/I2 cell line, four million cells were seeded onto each of 3 poly-
glycolic acid (PGA) scaffolds (5mm diameter × 2mm depth) threaded on stainless steel
wires suspended in spinner flasks containing the chondrocyte suspension. After seeding, the
resultant cell constructs were transferred to culture dishes and maintained under semi-static
conditions in DMEM; 10 % FCS; 10 mM HEPES; penicillin (100 U/ml)/streptomycin (0.1
mg/ml); 1× non-essential amino acids; 1 µg/ml insulin; 50 µg/ml ascorbic acid with 800 ng/
ml puromycin on a gently rotating orbital shaker for 40 days. The culture medium was
changed every 3–4 days. Both the cell seeding method and subsequent culture methods have
been described fully previously (Crawford and Dickinson, 2004). At the end of the culture
period, lentivirally transduced tissue constructs were frozen at ᙐ20 C for analysis of the
proteoglycan content by measurement of the glycosaminoglycan content, while retrovirally
transduced tissue constructs were weighed, bisected and one half mounted in the
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cryoprotectant OCT, frozen in liquid nitrogen and 8µm frozen sections taken for histology
and immunohistochemistry. The remaining construct halves were frozen at ᙐ20 °C for
glycosaminoglycan assay.
2.7. Functional Assays and controls
The quantity of sulphated glycosaminoglycans (GAGs) in tissue constructs was measured by
the standard colorimetric dimethylmethylene blue (DMMB) assay (Farndale et al., 1986).
The amount of DNA present in each construct was quantified using the ‘DNAQF’ kit
according to the manufacturer’s instructions (Sigma-Aldrich). The rate of formation of the
reduced form of the fluorescent vital dye, Alamar Blue™ was used to indicate the cell
viability/activity of chondrocyte constructs. Constructs were incubated with Alamar Blue™
according to the manufacturer’s instructions. In brief, constructs were incubated with a 10%
concentration of the commercial dye solution and the amount of reduced dye determined by
measurement of the optical density of the dye solution at 600 nm and 570 nm. Staining with
Toluidine Blue was carried out according to standard histological techniques. Cryosections
(8 ȝm) of the engineered constructs were air dried, fixed and stained with 1% Toluidine
Blue using routine laboratory protocols to detect GAG. Collagen II was detected
immunohistochemically (Kafienah and Sims, 2004) using monoclonal antibodies against
collagen type II and type I (Southern Biotechnology, Birmingham, USA).
2.8. Statistical Analysis
Statistical analysis was carried out using either Microsoft Excel 2007 (Washington, USA),
or Prism 4.0 (GraphPad Software Inc., San Diego, USA). Pairwise comparisons were made
using Student’s t test, while multiple comparisons were made using one-way ANOVA and
Dunnett’s post-hoc test.
3. Results and discussion
3.1. Aggrecanase expression in immortalized chondrocytes
There has not been a comprehensive study of the expression of all 6 aggrecanases in our
three well-known immortalized chondrocyte cell-lines C-20A4, C-28/I2 and T/C-28a2
(Finger et al., 2003; Goldring et al., 1994; Koshy et al., 2002). We therefore sought to
determine using real-time PCR, which aggrecanases were expressed and were the most
highly induced by pro-inflammatory cytokines in these cell lines. Figure 1 shows that 4 of
the aggrecanases (ADAMTS-1, -5, -9, and -15) were readily detectable in all three lines
(with the exception of C-20/A4, in which ADAMTS-9 was not detected). Neither
ADAMTS-4 nor ADAMTS-8 was expressed in any of the three lines, in agreement with
previous reports including our own (Kevorkian et al., 2004; Hui et al., 2005; Finger et al.,
2003). The transcripts most consistently up-regulated by treatment with a mix of cytokines,
IL-1ȕ, TNFĮ and IFNȖ, for 6 h were ADAMTS-5 and -9. Interestingly, in the T/C-28a2 cell-
line, ADAMTS-9 was the only transcript to be up-regulated by cytokines. In fact this was
due to a relatively higher constitutive level of expression for the 3 other transcripts rather
than a simple lack of induction. Since the aggrecanase expression profile of the C-28/I2 cell-
line in response to cytokines most closely resembled that of primary human articular
chondrocytes (Hui et al., 2005); we concluded that this cell-line could be used as an initial
simple chondrocyte model, in which to study the knock-down of ADAMTS gene expression
and begin to identify some of the resulting functional consequences.
3.2. Knock-down of ADAMTS-5 and -9 expression
Using lentiviral shRNA construct sets, for which 4 to 5 were designed and supplied per
target gene (Moffat et al., 2006), we generated viral particles and transduced C-28/I2
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chondrocytes. Cells expressing shRNA were selected using puromycin and maintained as
stably transduced populations. Expression of the targeted transcript was assessed by real-
time PCR and compared to the level of expression in cells that had been transduced with the
non-targeted (‘scrambled’) shRNA. Figure 2 shows the level of knock-down of ADAMTS-5
expression in cells transduced with each of the 5 target shRNAs designed for this transcript
(TRCN0000050493, 50494, 50495, 50496 and 50497), expressed as a percentage of the
amount of transcript in control cells. The highest level of knockdown was achieved with
shRNA 50496 (96 ± 1.56 %), although knockdown was also seen with constructs 50494 (44
± 3.87 %) and 50497 (79 ± 1.86 %).
Figure 3 similarly shows the knock-down of ADAMTS-9 expression, where the 5 shRNAs
available were TRCN0000046633, 46634, 46635, 46636 and 46637, although 46637-
transduced cells did not survive selection. shRNA 46633 provided the highest degree of
knock-down (70 ± 2.8 %), while knock-down was also seen with shRNA 46634 (39 ± 3.79
%).
We have presented validation of the lentiviral shRNA target sets provided for these 2 genes
by the RNAi consortium, and demonstrate a high degree of mRNA suppression (70–90 %)
by comparison to many other RNAi reports.
3.3. Matrix deposition in aggrecanase knock-down tissue constructs
We previously demonstrated that immortalized chondrocyte cell-lines can be grown in a 3D
culture (Finger et al., 2003; Goldring, 2004) as pellets, or for a limited time as cultures
suspended in alginate gels. In pellet or alginate, the immortalized chondrocytes will secrete
ECM components, and although little ECM is formed, the matrix components are similar to
that of 3D cultures of differentiated primary cells (Tare et al., 2005; Goldring, 2004).
Indeed, we have found that C-28/I2 cells grown as classic pellet cultures produce collagen II
and proteoglycans as detected by immunohistochemistry (data not shown). Hence, these cell
lines are a useful rudimentary chondrocyte model to enable selection of relevant shRNA
sequences in our experiments.
We seeded C-28/I2 cell populations that stably expressed either a lentiviral empty cloning
vector (no shRNA), or ‘scrambled’ shRNA or shRNA targeting either ADAMTS-5 or
ADAMTS-9 onto PGA scaffolds and cultured them under standard conditions (Crawford
and Dickinson, 2004) with inclusion of puromycin, for 40 days. At the end of the culture
period, rudimentary cellular constructs had formed and, although they did not yield an
extracellular matrix of the quality of engineered cartilage made from differentiated primary
cells, they did produce detectable GAG incorporation. Figure 4 shows the amount of GAG
present in each tissue construct, normalized to the amount of DNA present in the constructs.
We found that relative to the ‘scrambled’ shRNA-expressing control constructs,
ADAMTS-5 depleted cells formed constructs that incorporated a significantly larger
quantity of GAGs (40 % more), implying that greater amounts of matrix are deposited by
cells lacking this enzyme. In addition, ADAMTS-9 depleted cells incorporated 24 % more
GAGs than the controls, however statistical analysis did not show significance in this
comparison. Real-time PCR analysis of aggrecan and collagen II (COL2A1) transcripts
confirmed that the observed increase in GAG deposition by knock-down chondrocytes was
not due to increased levels of synthesis of these matrix proteins (data not shown). Although
there are several conclusive studies demonstrating a role for ADAMTS-5 in matrix turnover
(Glasson et al., 2005; Song et al., 2007), our data also suggest a possible role for
ADAMTS-9 in human chondrocytes. Expression studies including our own data (Figure 1)
do in fact show expression and cytokine-mediated up-regulation of ADAMTS-9 often over
and above the levels of the other aggrecanases (Demircan et al., 2005).
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We also seeded C-28/I2 cells stably expressing retroviral ADAMTS-5 or control shRNAs
for which we have previously shown that ADAMTS-5 expression is knocked down by > 90
% (Coughlan et al., 2009), on PGA scaffolds using the same methodology as that described
above. Again, only a limited amount of ECM was formed by the immortalised chondrocytes
compared to constructs of primary chondrocytes. However, both control and ADAMTS-5
knock-down constructs formed a rudimentary ECM which stained positively for the hyaline
cartilage marker collagen II and showed proteoglycan deposition (Figure 5A) There was a
significant difference in size and weight for the control constructs (11.3 mg and 7.7 mg)
relative to ADAMTS-5 knockdown constructs (38.4 mg and 47.9 mg), as well as a
significantly larger quantity of GAGs incorporated by ADAMTS-5 knock-down constructs
(1.8–4 fold increase over the control, Figure 5B). These results suggested that the
ADAMTS-5 knock-down chondrocytes formed more extracellular matrix than the control
cells. An increase in ECM production would mean that the fibres of the scaffold were
covered by ECM components more rapidly than the control constructs. This, in turn, would
reduce the rate at which the PGA would dissolve in the ADAMTS-5 knock-down construct,
and the slower scaffold dissolution would contribute to the increased construct weight
observed with the ADAMTS-5 knock-down construct. Absolute quantification of the
cellular activity of 3D constructs is not possible since it is difficult to ensure complete dye
penetration into the centre of constructs containing much ECM. However, use of the vital
dye Alamar Blue™ does give a reasonable indication of cellular activity in the immortalised
chondrocyte constructs, as the limited ECM deposited by these cells would not prevent dye
penetration into the constructs. Interestingly, there was no significant difference in the cell
activity as determined by Alamar Blue™ (Figure 5B), which suggested that there was no
significant difference in the cellular activity or cell number in the control versus
ADAMTS-5 knock-down constructs.
It is now well established that the aggrecanases have a pathological role in arthritis, and
most studies have focussed on aggrecanases 1 and 2 (ADAMTS-4 and -5 respectively). In a
mouse model of OA, Glasson et al. (2005) and Stanton et al. (2005) showed that
ADAMTS-5 gene knock-out was sufficient to prevent aggrecan loss and cartilage erosion,
while in mice ADAMTS-4 was not the enzyme involved (Stanton et al., 2005). In a porcine
3D culture model, ADAMTS-4 was found to be the critical aggrecanase responsible for
degrading aggrecan upon IL-1 administration (Powell et al., 2007). In bovine cartilage
explants treated with cytokines, both ADAMTS-4 and -5 are implicated in aggrecanolysis
(Tortorella et al., 2001). In fact a recent study using human cartilage explants transiently
transfected with short interfering RNA (siRNA) showed that both genes are also involved in
aggrecan loss in IL-1 treated or OA human cartilage (Song et al., 2007). Our study was
designed to investigate the effect of stable knock-down of aggrecanase genes on the
deposition of ECM by chondrocytes as they form de novo rudimentary tissue, since we
reasoned that increased quantity of matrix may be observed in the absence of aggrecanase
enzymes. Indeed, we show that knock-down of ADAMTS-5 expression results in increased
matrix in 3D constructs. Our future aim is to similarly knock-down expression of ADAMTS
genes in human primary articular chondrocytes and use them to tissue-engineer transplant
quality cartilage. This will reveal whether ablation of aggrecanase expression improves the
quality of tissue-engineered cartilage in line with our current observations. As such, our
investigations could be of great importance to establishing strategies for future cartilage
tissue engineering.
4. Conclusions
The results obtained with immortalised human chondrocyte cell lines suggested that both
ADAMTS-5 and ADAMTS-9 may be important in the turnover and formation of cartilage
ECM. Hence, depletion of ADAMTS-5 and possibly ADAMTS-9 in primary chondrocytes
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may result in better quality ECM formation in tissue-engineered neocartilage constructs.
Based on our results, and in agreement with previous studies, ADAMTS-5 is a potential
therapeutic target in arthritic disease. We now aim to use our knock-down shRNA constructs
to deplete these and the other ADAMTSs, especially ADAMTS-4, in primary human
chondrocytes. Further study should help to clarify which of these enzymes play key roles in
the aggrecanolysis of native arthritic cartilage.
In summary, we have generated and successfully used a tissue culture model to study the
role of proteolytic aggrecanase enzymes in cartilage. This combines RNAi knock-down in a
chondrocyte cell-line with growth of rudimentary 3D tissue constructs that produce small
amounts of matrix molecules. Using this model we have provided evidence for a role for
ADAMTS-5 and possibly also ADAMTS-9 in the turnover of ECM.
Acknowledgments
We thank Dr Dave Buttle, Victoria Howarth, Helen Waller, Jenny Mundy and Prof Mimoun Azzouz for help and
advice. This study was performed according to ethical guidelines.
Supported by BBSRC Grant Number: BB/E013791/1 and NIH Grant Number: R01-AG022021
References
Abbaszade I, Liu RQ, Yang F, Rosenfeld SA, Ross OH, Link JR, Ellis DM, Tortorella MD, Pratta
MA, Hollis JM, Wynn R, Duke JL, George HJ, Hillman MC Jr, Murphy K, Wiswall BH, Copeland
RA, Decicco CP, Bruckner R, Nagase H, Itoh Y, Newton RC, Magolda RL, Trzaskos JM, Hollis
GF, Arner EC, Burn TC. Cloning and characterization of ADAMTS11, an aggrecanase from the
ADAMTS family. J Biol Chem. 1999; 274:23443–23450. [PubMed: 10438522]
Arner EC, Pratta MA, Trzaskos JM, Decicco CP, Tortorella MD. Generation and characterization of
aggrecanase. A soluble, cartilage-derived aggrecan-degrading activity. J Biol Chem. 1999;
274:6594–6601. [PubMed: 10037754]
Arner EC. Aggrecanase-mediated cartilage degradation. Curr Opin Pharmacol. 2002; 2:322–329.
[PubMed: 12020478]
Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, Mitchell P, Hambor J,
Diekmann O, Tschesche H, Chen J, Van Wart H, Poole AR. Enhanced cleavage of type II collagen
by collagenases in osteoarthritic articular cartilage. J Clin Invest. 1997; 99:1534–1545. [PubMed:
9119997]
Caterson B, Flannery CR, Hughes CE, Little CB. Mechanisms involved in cartilage proteoglycan
catabolism. Matrix Biol. 2000; 19:333–344. [PubMed: 10963994]
Collins-Racie LA, Flannery CR, Zeng W, Corcoran C, Annis-Freeman B, Agostino MJ, Arai M,
DiBlasio-Smith E, Dorner AJ, Georgiadis KE, Jin M, Tan X-Y, Morris EA, LaVallie ER.
ADAMTS-8 exhibits aggrecanase activity and is expressed in human articular cartilage. Matrix
Biol. 2004; 23:219–230. [PubMed: 15296936]
Coughlan, T.; Crawford, A.; Hatton, P.; Barker, M. Genetic modification of chondrocytes using viral
vectors. In: Haycock, JW., editor. Methods in Molecular Biology-3D Cell Culture. Totowa, NJ,
USA: Humana Press; 2009. In Press
Crawford A, Dickinson SC. Chondrocyte isolation, expansion and culture on polymer scaffolds.
Methods in Mol. Biol. 2004; 238:147–157. [PubMed: 14970445]
Demircan K, Hirohata S, Nishida K, Hatipoglu OF, Oohashi T, Yonezawa T, Apte S, Ninomiya Y.
ADAMTS-9 is synergistically induced by interleukin-1ȕ and tumour-necrosis factor-Į in OUMS-27
chondrosarcoma cells and in human chondrocytes. Arthritis Rheum. 2005; 52:1451–1460.
[PubMed: 15880812]
Dodge GR, Poole AR. Immunohistochemical detection and immunochemical analysis of type II
collagen degradation in human normal, rheumatoid and osteoarthritic articular cartilages and in
explants of bovine articular cartilage cultured with interleukin-1. J Clin Invest. 1989; 83:647–661.
[PubMed: 2783591]
Coughlan et al. Page 8
J Tissue Eng Regen Med. Author manuscript; available in PMC 2011 December 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated
glycosaminoglycans by use of demethylmethyleneblue. Biochim Biophys Acta. 1986; 883:173–
177. [PubMed: 3091074]
Finger F, Schörle C, Zien A, Gebhard P, Goldring MB, Aigner T. Molecular phenotyping of human
chondrocyte cell lines T/C-28a2, T/C-28a4, and C-28/I2. Arthritis Rheum. 2003; 48:3395–3403.
[PubMed: 14673991]
Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma H-L, Flannery CR, Peluso D, Kanki K,
Yang Z, Majumdar MK, Morris EA. Deletion of active ADAMTS5 prevents cartilage degradation
in a murine model of osteoarthritis. Nature. 2005; 434:644–648. [PubMed: 15800624]
Goldring MB, Birkhead JR, Suen LF, Yamin R, Mizuno S, Glowacki J, Arbiser JL, Apperley JF.
Interleukin-1 beta-modulated gene expression in immortalized human chondrocytes. J Clin Invest.
1994; 94:2307–2316. [PubMed: 7989586]
Goldring, MB. Culture of immortalized chondrocytes and their use as models of chondrocyte function.
In: Sabatini, M.; Pastoureau, P.; De Ceuninck, F., editors. Methods in Molecular Medicine-
Cartilage and Osteoarthritis Volume 1: Cellular and Molecular Tools. Totowa, NJ, USA: Humana
Press; 2004. p. 37-52.
Hollander AP, Heathfield TF, Webber C, Iwata Y, Bourne R, Rorabeck C, Poole AR. Increased
damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. J
Clin Invest. 1994; 93:1722–1732. [PubMed: 7512992]
Hui W, Barksby HE, Young DA, Cawston TE, McKie N, Rowan AD. Oncostatin M in combination
with tumour necrosis factor {alpha} induces a chondrocyte membrane associated aggrecanase that
is distinct from ADAMTS aggrecanase-1 or -2. Ann Rheum Dis. 2005; 64:1624–1632. [PubMed:
15883123]
Kafienah W, Al-Fayez F, Hollander AP, Barker MD. Inhibition of cartilage degradation. Arthritis
Rheum. 2003; 48:709–718. [PubMed: 12632424]
Kafienah W, Sims TJ. Biochemical methods for the analysis of tissue-engineered cartilage. Methods in
Mol. Biol. 2004; 238:217. [PubMed: 14970450]
Kevorkian L, Young DA, Darrah C, Donell ST, Shepstone L, Porter S, Brockbank SM, Edwards DR,
Parker AE, Clark IM. Expression profiling of metalloproteinases and their inhibitors in cartilage.
Arthritis Rheum. 2004; 50:131–141. [PubMed: 14730609]
Knäuper V, López-Otin C, Smith B, Knight G, Murphy G. Biochemical characterization of human
collagenase-3. J Biol Chem. 1996; 271:1544–1550. [PubMed: 8576151]
Koshy PJ, Lundy CJ, Rowan AD, Porter S, Edwards DR, Hogan A, Clark IM, Cawston TE. The
modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by
interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse
transcription-polymerase chain reaction. Arthritis Rheum. 2002; 46:961–967. [PubMed:
11953973]
Kuno K, Okada Y, Kawashima H, Nakamura H, Miyasaka M, Ohno H, Matsushima K. ADAMTS-1
cleaves a cartilage proteoglycan, aggrecan. FEBS Lett. 2000; 478:241–245. [PubMed: 10930576]
Kurth T, Hedbom E, Shintani N, Sugimoto M, Chen FH, Haspl M, Martinovic S, Hunziker EB.
Chondrogenic potential of human synovial mesenchymal stem cells in alginate. Osteoarthr
Cartilage. 2007; 15:1178–1189.
Little CB, Mittaz L, Belluoccio D, Rogerson FM, Campbell IK, Meeker CT, Bateman JF, Pritchard
MA, Fosang AJ. ADAMTS-1-knockout mice do not exhibit abnormalities in aggrecan turnover in
vitro or in vivo. Arthritis Rheum. 2005; 52:1461–1472. [PubMed: 15880348]
Lohmander LS, Neame PJ, Sandy JD. The structure of aggrecan fragments in human synovial fluid.
Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint
injury, and osteoarthritis. Arthritis Rheum. 1993; 36:1214–1222. [PubMed: 8216415]
Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, Piqani B, Eisenhaure TM, Luo
B, Grenier JK, Carpenter AE, Foo SY, Stewart SA, Stockwell BR, Hacohen N, Hahn WC, Lander
ES, Sabatini DM, Root DE. A lentiviral RNAi library for human and mouse genes applied to an
arrayed viral high-content screen. Cell. 2006; 124:1283–1298. [PubMed: 16564017]
Coughlan et al. Page 9
J Tissue Eng Regen Med. Author manuscript; available in PMC 2011 December 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Mohamed-Ali H. Influence of interleukin-1 beta, tumour necrosis factor alpha and prostaglandin E2 on
chondrogenesis and cartilage matrix breakdown in vitro. Rheumatol Int. 1995; 14:191–199.
[PubMed: 7724995]
Mort JS, Dodge GR, Roughley PJ, Liu J, Finch SJ, DiPasquale G, Poole AR. Direct evidence for
active metalloproteinases mediating matrix degradation in interleukin 1-stimulated human articular
cartilage. Matrix. 1993; 13:95–102. [PubMed: 8492744]
Mort JS, Billington CJ. Articular cartilage and changes in arthritis: matrix degradation. Arthritis Res.
2001; 3:337–341. [PubMed: 11714387]
Nagase H, Kashiwagi M. Aggrecanases and cartilage matrix degradation. Arthritis Res Ther. 2003;
5:94–103. [PubMed: 12718749]
Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y. Membrane type 1 matrix metalloproteinase
digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem. 1997;
272:2446–2451. [PubMed: 8999957]
Porter S, Clark IM, Kevorkian L, Edwards DR. The ADAMTS metalloproteinases. Biochem J. 2005;
386:15–27. [PubMed: 15554875]
Powell AJ, Little CB, Hughes CE. Low molecular weight isoforms of the aggrecanases are responsible
for the cytokine-induced proteolysis of aggrecan in a porcine chondrocyte culture system. Arthritis
Rheum. 2007; 56:3010–3019. [PubMed: 17763444]
Rodríguez-Manzaneque JC, Westling J, Thai SN, Luque A, Knauper V, Murphy G, Sandy JD, Iruela-
Arispe ML. ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by
metalloproteinase inhibitors. Biochem Biophys Res Commun. 2002; 293:501–508. [PubMed:
12054629]
Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan
in cartilage. Nature. 1986; 322:547–549. [PubMed: 3736671]
Sandy JD, Neame PJ, Boynton RE, Flannery CR. Catabolism of aggrecan in cartilage explants.
Identification of a major cleavage site within the interglobular domain. J Biol Chem. 1991;
266:8683–8685. [PubMed: 2026585]
Sandy JD, Flannery CR, Neame PJ, Lohmander LS. The structure of aggrecan fragments in human
synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves
the Glu 373-Ala 374 bond of the interglobular domain. J Clin Invest. 1992; 89:1512–1516.
[PubMed: 1569188]
Sandy JD, Verscharen C. Analysis of aggrecan in human knee cartilage and synovial fluid indicates
that aggrecanase (ADAMTS) activity is responsible for the catabolic turnover and loss of whole
aggrecan whereas other protease activity is required for C-terminal processing in vivo. Biochem J.
2001; 358:615–626. [PubMed: 11535123]
Somerville RP, Longpre JM, Jungers KA, Engle JM, Ross M, Evanko S, Wight TN, Leduc R, Apte
SS. Characterisation of ADAMTS-9 and ADAMTS-20 as a distinct ADAMTS subfamily related
to Caenorhabditis elegans GON-1. J Biol Chem. 2003; 278:9503–9513. [PubMed: 12514189]
Song R-H, Tortorella MD, Malfait A-M, Alston JT, Yang Z, Arner EC, Griggs DW. Aggrecan
degradation in human articular cartilage explants is mediated by both ADAMTS-4 and
ADAMTS-5. Arthritis Rheum. 2007; 56:575–585. [PubMed: 17265492]
Stanton H, Rogerson FM, East CJ, Golub SB, Lawlor KE, Meeker CT, Little CB, Last K, Farmer PJ,
Campbell IK, Fourle AM, Fosang AJ. ADAMTS5 is the major aggrecanase in mouse cartilage in
vivo and in vitro. Nature. 2005; 434:648–652. [PubMed: 15800625]
Tare RS, Howard D, Pound JC, Roach HI, Oreffo RO. Tissue engineering strategies for cartilage
generation--micromass and three dimensional cultures using human chondrocytes and a
continuous cell line. Biochem Biophys Res Commun. 2005; 333:609–621. [PubMed: 15946652]
Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis JM, Liu R, Rosenfeld SA, Copeland RA,
Decicco CP, Wynn R, Rockwell A, Yang F, Duke JL, Solomon K, George H, Bruckner R, Nagase
H, Itoh Y, Ellis DM, Ross H, Wiswall BH, Murphy K, Hillman MC Jr, Hollis GF, Newton RC,
Magolda RL, Trzaskos JM, Arner EC. Purification and cloning of aggrecanase-1: a member of the
ADAMTS family of proteins. Science. 1999; 284:1664–1666. [PubMed: 10356395]
Coughlan et al. Page 10
J Tissue Eng Regen Med. Author manuscript; available in PMC 2011 December 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Tortorella MD, Malfait A-M, Deccico C, Arner E. The role of ADAM-TS4 (aggrecanase-1) and
ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthr Cartilage. 2001;
9:539–552.
Yamaji, N.; Nishimura, K.; Abe, K.; Ohara, O.; Nagase, T.; Nomura, N. Novel metalloproteinase
having aggrecanase activity Pat. Japan: Yamanouchi Pharmaceutical Co. Ltd; 2001.
Coughlan et al. Page 11
J Tissue Eng Regen Med. Author manuscript; available in PMC 2011 December 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. Expression of the 6 aggrecanases in chondrocyte cell-lines
Transcript levels for ADAMTS-1, -4, -5, -8, -9 and -15 in cells with (filled bars) and without
(open bars) 6 h stimulation with cytokine mix (10ng/ml IL1-ȕ, 500ng/ml TNF-Į, 1,000U/ml
IFN-Ȗ) were assessed by real-time PCR. Data are expressed as mean ± S.E.M. mRNA levels
were normalized to those of the control cyclophilin-E transcript and n=2. *p<0.05 relative to
controls using Student’s t test. ADAMTS-4 and ADAMTS-8 expression was undetectable in
any of the cell-lines.
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Figure 2. Knock-down of ADAMTS-5 in C-28/I2 chondrocytes
ADAMTS-5 expression was assessed by real-time PCR in cells stably transduced with
lentiviral shRNA constructs either targeting the ADAMTS-5 gene (50493-7), or untargeted
(‘scrambled’) as control. Data are expressed as mean ± S.E.M., normalized to cyclophilin-E
and calibrated so that mean ‘scram’= 100 %. n=4. Representative of 3 independent
experiments. *p<0.05 relative to ‘scram’ using Student’s t test.
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Figure 3. Knock-down of ADAMTS-9 in C-28/I2 chondrocytes
ADAMTS-9 expression was assessed by real-time PCR in cells stably transduced with
lentiviral shRNA constructs either targeting the ADAMTS-9 gene (46633-6), or untargeted
(‘scrambled’) as control. Data are expressed as mean ± S.E.M., normalized to cyclophilin-E
and calibrated so that mean ‘scram’= 100 %. n=4. Representative of 3 independent
experiments. *p<0.05 relative to ‘scrambled’ using Student’s t test.
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Figure 4. sGAG content of lentiviral knock-down tissue constructs
Lentivirally transduced C-28/I2 cell-lines were seeded and allowed to grow into rudimentary
tissue constructs on polyglycolic acid scaffolds. Quantification of GAGs in each construct
was carried out using the DMMB assay and repeated twice. Data are expressed as mean ±
S.E.M. normalized to amount of DNA per construct. n=3. *p<0.05 relative to ‘scrambled’
using one-way ANOVA and Dunnett’s post-hoc test.
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Figure 5. Properties of ADAMTS-5 knock-down C-28/I2 chondrocyte/PGA constructs
ADAMTS-5 retroviral knock-down cell-lines were cloned by limiting dilution. C-28/I2 cell-
lines were transduced with retrovirus and chondrocyte/PGA constructs formed as described
in the methods section. Figure 5A: Collagen II and proteoglycan deposition in C-28/I2
control and ADAMTS-5 knock-down constructs. Micrographs A, B and C are control
constructs and micrographs D, E and F are ADAMTS-5 knock-down constructs.
Micrographs A and D show non-specific immunohistochemical staining, as shown in the
micrographs some non-specific staining of the PGA fibres was observed. Micrographs B and
E show collagen II deposition detected by immunohistochemistry, micrographs C and F
show sections stained with Toluidine Blue to detect proteoglycan. Scale bars=200µm.
Figure 5B: Cellular activity of C-28/I2 control and ADAMTS-5 knock-down constructs as
determined by the reduction of Alamar Blue™ (left-hand panel) and total
glycosaminoglycan content of the constructs determined by quantification with 1,9-
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dimethylmethylene blue (right-hand panel). Data are expressed as mean ± S.E.M., n=2.
*p<0.05, using unpaired t test).
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